RT Journal Article
T1 Analysis of the Plasma Proteome Associated with Acute Coronary Syndrome: Does a Permanent Protein Signature Exist in the Plasma of ACS Patients?
A1 Dardé, Veronica
A1 Cuesta, Fernando de la
A1 Gil Dones, Félix
A1 Álvarez Llamas, Gloria
A1 Barderas, Maria
A1 Vivanco Martínez, Fernando
AB Acute coronary syndrome (ACS) is triggered by the occlusion of a coronary artery usually due to the thrombosis caused by an atherosclerotic plaque. The identification of proteins directly involved in the pathophysiological events underlying ACS will enable more precise diagnoses and a more accurate prognosis to be determined. Accordingly, we have performed a longitudinal study of the plasma proteome in ACS patients by 2-DE and DIGE. Plasma samples from patients, healthy controls, and stable coronary artery disease (CAD) patients were immunodepleted of the six most abundant proteins, and they were analyzed in parallel at four different times: 0 (on admission) and after 4, 60, and 180 days. From a total of 1400 spot proteins analyzed, 33 proteins were differentially expressed in ACS patients when compared with control subjects/stable patients. A small group of seven proteins that appear to be altered at admission remain affected for 6 months and also in the stable CAD patients. Interestingly, the maximum number of altered proteins was observed in the stable CAD patients. Some of the proteins identified had been previously associated with ACS whereas others (such as Alpha-1-B-glycoprotein, Hakata antigen, Tetranectin, Tropomyosin 4) constitute novel proteins that are altered in this pathology.
PB American Chemical Society
SN 1535-3893
YR 2010
FD 2010
LK https://hdl.handle.net/20.500.14352/94732
UL https://hdl.handle.net/20.500.14352/94732
LA eng
NO Dardé, Veronica M., et al. «Analysis of the Plasma Proteome Associated with Acute Coronary Syndrome: Does a Permanent Protein Signature Exist in the Plasma of ACS Patients?» Journal of Proteome Research, vol. 9, n.o 9, septiembre de 2010, pp. 4420-32. https://doi.org/10.1021/pr1002017.
NO This work was supported by Comunidad de Madrid (Proteomarkers), Fina Biotech, Sociedad Española de Aterosclerosis, FIS (PI-080970), Mutua Madrileña  (20174/ 004), Ministerio de Ciencia (BFU-2005,08838)
NO Comunidad de Madrid
NO Fina Biotech
NO Sociedad Española de Aterosclerosis
NO Mutua Madrileña
NO Ministerio de Ciencia (España)
DS Docta Complutense
RD 5 abr 2025